| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
HIV integrase. BMS-538203 is a novel HIV integrase inhibitor. HIV integrase is a viral enzyme responsible for the integration of viral DNA into the host cell genome, a critical step in the HIV replication cycle. The compound inhibits the enzymatic activity of HIV integrase, preventing viral DNA integration and thus blocking viral replication. The fluoro-benzyl group may enhance binding affinity to the enzyme.
|
|---|---|
| ln Vitro |
BMS-538203 is a novel and highly efficient HIV integrase inhibitor and antiviral agent. BMS-538203 was discovered by a hit-to-clinical candidate pathway that resulted in 50- and 2000-fold improvements in enzyme-inhibition and antiviral activity without an increase in molecular weight or change in molecular topology. The original hit, 1 (mw = 268) was optimized in a stepwise manner. Potential covalent protein-binding moieties were removed by reducing the number of the ketone groups. High enzyme inhibition activity was achieved by optimizing the aryl-portion of the molecule. Protein binding was reduced by replacing the standard amide by the corresponding methyl-hydroxamide. This eventually led to the discovery of compound 2 (BMS-538203, mw = 269) a highly efficient inhibitor and antiviral agent.
In vitro, BMS-538203 demonstrates potent inhibition of HIV integrase in enzyme assays. The compound shows improvements in enzyme-inhibition activity. As an HIV integrase inhibitor, BMS-538203 prevents the integration of viral DNA into the host genome, a critical step in the HIV replication cycle. The compound's antiviral activity has been demonstrated in cell-based assays. |
| ln Vivo |
Detailed in vivo activity data for BMS-538203 are limited in publicly available sources. As an HIV integrase inhibitor, the compound is expected to demonstrate antiviral efficacy in animal models of HIV infection. The compound's mechanism of action targeting a viral enzyme essential for replication suggests potential for in vivo efficacy. However, HIV does not infect standard laboratory animals, and efficacy studies typically require specialized models such as humanized mice or non-human primates.
|
| Enzyme Assay |
The HIV integrase enzyme inhibition assay for BMS-538203 involves recombinant HIV integrase incubated with a DNA substrate (viral DNA ends) in the presence of varying concentrations of the compound. Integrase activity is measured by quantifying the integration of labeled DNA into a target DNA or by detecting the strand transfer product. IC₅₀ values are calculated from dose-response curves. The assay may use radioactive or fluorescent-labeled substrates for detection.
|
| Cell Assay |
HIV-infected cells (e.g., MT-4 cells, CEM cells, or other susceptible cell lines) are cultured in appropriate medium. Cells are infected with HIV at a defined multiplicity of infection and treated with varying concentrations of BMS-538203. Viral replication is assessed by measuring HIV p24 antigen production by ELISA, viral RNA by RT-PCR, or by cytopathic effect reduction. Cytotoxicity is evaluated in parallel using uninfected cells treated with the same concentrations of the compound to determine the selectivity index.
|
| Animal Protocol |
In vivo efficacy studies for HIV integrase inhibitors typically involve humanized mouse models or non-human primates. In humanized mice, animals are engrafted with human hematopoietic stem cells to reconstitute a human immune system susceptible to HIV infection. Mice are infected with HIV and treated with BMS-538203 at various doses and schedules. Viral load is measured in plasma by RT-PCR, and CD4+ T cell counts are monitored. Tissues are analyzed for viral reservoirs at study termination.
|
| ADME/Pharmacokinetics |
BMS-538203 has a molecular weight of 269.23 g/mol and a molecular formula of C₁₂H₁₂FNO₅. Detailed pharmacokinetic parameters are not extensively published. As a small molecule, BMS-538203 is expected to be orally bioavailable. The compound's molecular weight of 269.23 g/mol is within the favorable range for oral drug absorption. Pharmacokinetic studies would be required to support further development as an antiviral agent.
|
| Toxicity/Toxicokinetics |
Detailed toxicology data for BMS-538203 are limited in publicly available sources. As an HIV integrase inhibitor, the compound would have undergone standard preclinical safety evaluation, including in vitro cytotoxicity profiling, hERG channel assessment, and in vivo toxicology studies in rodents and dogs. The compound's selectivity for viral integrase over human enzymes suggests a favorable safety profile.
|
| References | |
| Additional Infomation |
BMS-538203 is a novel HIV integrase inhibitor with a molecular formula of C₁₂H₁₂FNO₅ and a molecular weight of 269.23 g/mol. It demonstrates improvements in enzyme-inhibition and antiviral activity. The compound's mechanism of action involves interaction with HIV integrase, with the fluoro-benzyl group enhancing binding affinity. BMS-538203 represents a promising lead compound for the development of novel HIV therapeutics with a favorable molecular weight and potency profile.
|
| Molecular Formula |
C12H12FNO5
|
|
|---|---|---|
| Molecular Weight |
269.23
|
|
| Exact Mass |
269.07
|
|
| CAS # |
543730-41-2
|
|
| Related CAS # |
|
|
| PubChem CID |
54706524
|
|
| Appearance |
Typically exists as solid at room temperature
|
|
| LogP |
1.242
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
6
|
|
| Rotatable Bond Count |
5
|
|
| Heavy Atom Count |
19
|
|
| Complexity |
363
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
O=C(O)/C(O)=C/C(N(CC1=CC=C(F)C=C1)OC)=O
|
|
| InChi Key |
GACIOSIZKMLELV-POHAHGRESA-N
|
|
| InChi Code |
InChI=1S/C12H12FNO5/c1-19-14(11(16)6-10(15)12(17)18)7-8-2-4-9(13)5-3-8/h2-6,15H,7H2,1H3,(H,17,18)/b10-6-
|
|
| Chemical Name |
(Z)-4-[(4-fluorophenyl)methyl-methoxyamino]-2-hydroxy-4-oxobut-2-enoic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7143 mL | 18.5715 mL | 37.1430 mL | |
| 5 mM | 0.7429 mL | 3.7143 mL | 7.4286 mL | |
| 10 mM | 0.3714 mL | 1.8571 mL | 3.7143 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA